Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
Alseres Pharmaceuticals
HSMN NewsFeed - 16 Nov 2010
Neoprobe Names Executive Vice President, Chief Development Officer
Devices
Diagnostics
Oncology
Personnel
HSMN NewsFeed - 18 Sep 2008
The European Commission Grants Orphan Drug Designation to Alseres Pharmaceuticals' Spinal Cord Injury Treatment, Cethrin(R)
Biopharmaceuticals
Neurology
Regulatory
HSMN NewsFeed - 22 Aug 2008
Regenesis Biomedical Announces Additions to Board of Directors
Devices
Wound Care
Personnel
HSMN NewsFeed - 17 Apr 2008
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Biopharmaceuticals
Diagnostics
Neurology
HSMN NewsFeed - 24 Sep 2007
Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
Biopharmaceuticals
Neurology
HSMN NewsFeed - 27 Jun 2007
Alseres Pharmaceuticals Announces FDA Clearance to Increase Dose Level in Cethrin(R) Phase I/IIa Clinical Trial for Acute Spinal Cord Injury at U.S. Sites
Biopharmaceuticals
Neurology
FDA
HSMN NewsFeed - 8 Jun 2007
Boston Life Sciences, Inc. Changes Name to Alseres Pharmaceuticals, Inc.
Biopharmaceuticals
Return to NewsFeed
